Vienna/Neufeld an der Leitha +++ Sanochemia Pharmazeutika continues to strengthen its position in medical imaging with the submission of an application for its liver-specific contrast agent in multiple European countries.
The product based on iron-containing nanoparticles (SPIO) aims to detect focal liver lesions in adults. It is already approved in Sweden by Sanochemia and in Germany by b.e.imaging.
This important step enables additional diagnostic possibilities for radiologists and is in line with Sanochemia’s ambition to position itself as a leading provider of specialized MRI and CT contrast agents. Sanochemia is committed to further expand horizons in MR Imaging and improving patient care worldwide.
Complementation of MRI liver diagnostics
“With Resotran, we are opening up expanded diagnostic options for liver specialists,” said Thomas Erkinger, Managing Director of Sanochemia. “For us, this is an important step on the way to becoming a provider of organ-specific contrast agents and to gadolinium-free imaging.”